Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

ENZ, PWRM, WFR, PBY, NCI - Stock Updates! from




MEMC Electronic Materials Inc. (NYSE:WFR) announced that it has received the final milestone payment of 230 million Euros from First Reserve for the sale of a 70 megawatt (MW) photovoltaic (PV) power plant located in Northeast Italy, near the town of Rovigo. As previously announced, the Rovigo solar power plant was acquired by First Reserve for approximately 276 million Euros, through a joint venture established between First Reserve and SunEdison. In October 2010, First Reserve made an initial milestone payment of 46 million Euros to SunEdison and on December 23, 2010 funded the final 230 million Euro milestone payment.

MEMC Electronic Materials, Inc. designs, manufactures, and sells silicon wafers for the semiconductor industry worldwide. Its products include prime polished wafers, such as OPTIA and annealed products.


Pep Boys - Manny, Moe & Jack (NYSE:PBY) the nation’s leading automotive aftermarket service and retail chain, announced that its Board of Directors approved the payment of the next quarterly dividend of $0.03 per share payable on January 24, 2011 to shareholders of record on January 10, 2011. The annual dividend of $0.12 per share currently yields approximately 0.9%.

The Pep Boys Manny, Moe & Jack, together with its subsidiaries, operates a chain of stores that provides automotive repair and maintenance services; and sells automotive tires, parts, and accessories in the United States and Puerto Rico.


  Enzo Biochem, Inc. (NYSE:ENZ)

Bone Disorders


Osteoporosis, meaning "porous bones", is a condition of weakened and brittle bones that become more prone to fracture. The 10-billion dollar osteoporosis market is crowded with bone-preserving drugs such as bisphosphonates and selective estrogen receptor modulators, commonly referred to as SERMS. Bone-building drugs such as ENZ's candidate compounds offer the potential for promising alternatives.


One of the most challenging problems chronicled throughout the history of clinical dentistry is the loss of alveolar bone. Alveolar bone loss is characterized by a reduction in the height and volume of the maxillary and mandibular bones that underlie and support the teeth. The primary causes of alveolar bone loss are periodontitis and tooth loss, although osteoporosis may also contribute.

According to the literature (see Albandar JM 1999 J Periodontal., 70:13-29) roughly 35% of US adults between the ages of 30 and 90 have periodontitis. The lack of an effective treatment for periodontal bone loss has encouraged the continued search for a successful therapeutic approach. We believe that ENZ's candidate bone-building drugs may be such an approach.

“We are pleased to report that our program instituted this quarter aimed at making Enzo more efficient and designed to produce more effective use of our assets is beginning to show results, as demonstrated by improved performance, ” said Barry Weiner, President of ENZ. “While we are in the early stages of this comprehensive program, the results experienced to date are very encouraging.”

“Moreover, in the first quarter, we achieved several milestones. We submitted Colon Sentry, a unique assay for risk-stratification of colon cancer occurrence, to the New York State Department of Health for approval. In addition, we began enrolling the first patients in our clinical trial of Optiquel, our candidate therapeutic for the treatment of autoimmune uveitis. We also continued to roll out proprietary products and systems designed to aid in drug development,” he added.

To learn more about ENZ visit:


Power3 Medical Products, Inc. (OTC:PWRM)

With the growth of information on the internet has growth the amount of time people spend on it, which has in turn generated a new market for internet advertising. Some of the wealthiest companies in the world have made sure that they get a piece of the internet marketing pie, and for a good reason.

"We are very excited to be finally ridding ourselves of litigation that has plagued us for several years now," stated Ira L. Goldknopf, President and Chief Scientific Officer of PWRM. "We have big plans for the future beginning with our upcoming acquisition of Rozetta-Cell and are about to enter a long and substantial growth phase marked by advances in our science and intellectual property. Given the imminent nature of many of these transactions and breakthroughs, we have decided, in consultation with the financiers of Rozetta-Cell, that the best course of action for Power3 is to settle many of these lawsuits so that we can focus our attention exclusively on the acquisition of Rozetta-Cell and the development of our combined businesses after the merger."

To learn more about PWRM visit:


Navigant Consulting Inc. (NYSE:NCI) announced the promotion of ten of the Company’s professionals to the position of Managing Director. “We are excited to announce the promotion of ten exemplary Navigant professionals to the position of Managing Director,” said Julie Howard, President and Chief Operating Officer. “The newly promoted professionals have consistently demonstrated leadership – providing critical thinking and pragmatic solutions to their clients; offering mentorship and development of their staff; and being overall stewards of the firm. We look forward to their continued contributions to Navigant’s success.”

Navigant Consulting, Inc., a specialty consulting firm, provides services to companies in addressing the challenges of uncertainty, risk, distress, and significant change.



Signup for FREE Daily Stock Alerts From


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.  Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).